APA (7th ed.) Citation

M, M., P, M., P, F., JM, G., A, d. l. F., J, S., . . . J, S. (2021, July). Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain [Corrigendum]. ClinicoEconomics and Outcomes Research.

Chicago Style (17th ed.) Citation

M, Mareque, et al. "Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain [Corrigendum]." ClinicoEconomics and Outcomes Research Jul. 2021.

MLA (9th ed.) Citation

M, Mareque, et al. "Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain [Corrigendum]." ClinicoEconomics and Outcomes Research, Jul. 2021.